1-甲基-1H-咪唑-4-磺酰氯 | 137049-00-4

• 物质功能分类: 化学试剂 - 有机试剂 - 酰卤
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-1H-咪唑-4-磺酰氯
• 中文别名: N-甲基-咪唑4-磺酰氯；1H-咪唑-1-甲基-4-磺酰氯；1-甲基咪唑-4-磺酰氯
• 英文名称: 1-methyl-1H-imidazole-4-sulfonyl chloride
• 英文别名: 1-methylimidazole-4-sulfonyl chloride
• CAS: 137049-00-4
• 化学式: C₄H₅ClN₂O₂S
• mdl: MFCD00068060
• 分子量: 180.615
• InChiKey: KXUGUWTUFUWYRS-UHFFFAOYSA-N

物化性质

• 熔点：
  88-91°C
• 沸点：
  366.9±15.0 °C(Predicted)
• 密度：
  1.60±0.1 g/cm3(Predicted)
• 溶解度：
  二甲基亚砜（微溶）

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  8
• 危险品标志：
  C
• 危险类别码：
  R14,R34,R29
• 危险品运输编号：
  3261
• 危险类别：
  8
• 安全说明：
  S22,S26,S30,S36/37/39,S45,S8
• 包装等级：
  III
• 危险性防范说明：
  P280,P305+P351+P338,P310
• 危险性描述：
  H314
• 储存条件：
  -20°C

SDS

Name:	1-Methyl-1H-imidazole-4-sulfonyl chloride 95+% Material Safety Data Sheet
Synonym:
CAS:	137049-00-4

Section 1 - Chemical Product MSDS Name:1-Methyl-1H-imidazole-4-sulfonyl chloride 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
137049-00-4	1-Methyl-1H-imidazole-4-sulfonyl chlor	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 137049-00-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 88 - 91 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H5ClN2O2S
Molecular Weight: 181

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, bases, amines, reducing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 137049-00-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
1-Methyl-1H-imidazole-4-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, N.O.S.*
Hazard Class: 8
UN Number: 1759
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, N.O.S.
Hazard Class: 8
UN Number: 1759
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 137049-00-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 137049-00-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 137049-00-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-1H-咪唑-4-磺酰氯 在 一水合肼 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 生成 1-methyl-1H-imidazole-4-sulfonyl hydrazide
  参考文献：
  名称：

  Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity

  摘要：

  Here, we describe the selection and optimization of a chemical series active in both a full-length and a fragment-based Huntington's disease (HD) assay. Twenty-four thousand small molecules were screened in a phenotypic HD assay, identifying a series of compounds bearing a 3-hydroxy-3-trifluoromethylpyrazole moiety as able to revert the toxicity induced by full-length mutant Htt by up to 50%. A chemical exploration around the series led to the identification of compound 4f, which demonstrated to be active in a Htt171-82Qrat primary striatal neuron assay and a PC12-Exon-1 based assay. This compound was selected for testing in R6/2 mice, in which it was well-tolerated and showed a positive effect on body weight and a positive trend in preventing ventricular volume enlargment. These studies provide strong rationale for further testing the potential benefits of 3-hydroxy-3-trifluoromethylpyrazoles in treating HD.

  DOI：

  10.1021/ml400251g
• 作为产物：
  描述：

  N-甲基咪唑 、 氯磺酸 、 盐酸 、 氯化亚砜 、 在 ice 、 Sodium sulfate-III 、 1H-咪唑-5-磺酸 、 乙醇 、 1H-咪唑-2-磺酸 作用下， 25.0~150.0 ℃ 、266.62 kPa 条件下， 反应 12.0h， 以Yield: 176 g (32% of theory) of colorless crystals were obtained (melting point: 89°-90° C.)的产率得到1-甲基-1H-咪唑-4-磺酰氯
  参考文献：
  名称：

  Imidazole compounds, processes for their preparation, pharmaceuticals

  摘要：

  化合物I的咪唑类化合物的公式为：##STR1## 其中R.sup.1 =烷基，R.sup.2和R.sup.3 =氢、卤素或烷基，X=OH或具有某些取代基的酰胺基团，其制备过程以及基于这些化合物的药物，特别用于预防和治疗循环障碍，尤其是微循环障碍及其引起的疾病，并且一些新的中间体用于制备公式I的化合物，这些中间体是1-甲基、1,2-二甲基和1-乙基-4-咪唑磺酰氯。

  公开号：

  US05356922A1

文献信息

• Benzene Sulfonamide Thiazole and Oxazole Compounds
  申请人：Adams Jerry Leroy

  公开号：US20090298815A1

  公开（公告）日：2009-12-03

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺胺和噁唑磺胺化合物，含有这些化合物的组合物，以及用作药物制剂的制备方法和使用方法。
• 1,3‐Benzodioxole‐Modified Noscapine Analogues: Synthesis, Antiproliferative Activity, and Tubulin‐Bound Structure
  作者：Cassandra Yong、Shane M. Devine、Anne‐Catherine Abel、Stefan D. Tomlins、Divya Muthiah、Xuexin Gao、Richard Callaghan、Michel O. Steinmetz、Andrea E. Prota、Ben Capuano、Peter J. Scammells

  DOI：10.1002/cmdc.202100363

  日期：2021.9.16

  To date, noscapine has been explored at the 1, 7, 6′, and 9′-positions, though the 1,3-benzodioxole motif in the noscapine scaffold that remains unexplored. The present investigation describes the design, synthesis and pharmacological evaluation of noscapine analogues consisting of modifications to the 1,3-benzodioxole moiety. This includes expansion of the dioxolane ring and inclusion of metabolically

  自从揭示了诺斯卡品的弱抗有丝分裂活性以来，在过去的二十年中进行了广泛的研究，目的是发现具有更高效力的诺斯卡品衍生物。迄今为止，已在 1, 7, 6' 和 9' 位置探索了诺斯卡品，尽管诺斯卡品支架中的 1,3-苯并二氧戊环基序仍未探索。本研究描述了对 1,3-苯并二氧戊环部分进行修饰的诺斯卡平类似物的设计、合成和药理学评价。这包括二氧戊环环的扩展和代谢稳健的氘和氟原子的加入。随后将有利的结构修饰结合到多功能化的诺斯卡品衍生物中，该衍生物也具有先前显示的修饰以促进 1-、6'-和 9'-位置的抗增殖活性。我们的研究工作提供了氘代诺斯卡品衍生物图14  e和含二恶英的类似物20作为有效的细胞毒剂，针对乳腺癌 (MCF-7) 细胞的EC 50值分别为 1.50 和 0.73 μM。在 NCI 筛选中，化合物20对黑色素瘤、非小细胞肺癌和脑癌、肾癌和乳腺癌的EC 50值也小于 2 μM。此外，化合
• BROMODOMAIN INHIBITORS FOR TREATING DISEASE
  申请人：Board of Regents, The University of Texas System

  公开号：US20160060260A1

  公开（公告）日：2016-03-03

  Disclosed herein are compounds and compositions useful in the treatment of bromodomain-containing protein-mediated diseases, such as cancer, having the structure of Formula I: Methods of inhibiting activity of a bromodomain-containing protein in a human or animal subject are also provided.

  本文披露了一种在治疗溴结构域含蛋白介导的疾病（如癌症）中有用的化合物和组合物，其具有Formula I的结构： 还提供了一种抑制人类或动物主体中溴结构域含蛋白活性的方法。
• [EN] COMPOUNDS AND THERAPEUTIC USES THEREOF<br/>[FR] COMPOSÉS ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：VIOGEN BIOSCIENCES LLC

  公开号：WO2020243457A1

  公开（公告）日：2020-12-03

  The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, diseases associated with over production of IL12/IL23, lysosomal storage disorders, filovirus infections, ischemia, neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, and frontotemporal dementia, viral infection including SARS-CoV-2, and other complications associated with the foregoing diseases and disorders.

  这项发明涉及化合物、药物组合物和方法，用于治疗癌症、全身性或慢性炎症、类风湿关节炎、糖尿病、肥胖症、T细胞介导的自身免疫疾病、与IL12/IL23过度产生相关的疾病、溶酶体贮积疾病、丝状病毒感染、缺血、包括阿尔茨海默病、肌萎缩侧索硬化和额颞叶痴呆症在内的神经退行性疾病、包括SARS-CoV-2的病毒感染，以及与上述疾病和疾病相关并发症。
• Application of a Catalytic Asymmetric Povarov Reaction using Chiral Ureas to the Synthesis of a Tetrahydroquinoline Library
  作者：Baudouin Gerard、Morgan Welzel O’Shea、Etienne Donckele、Sarathy Kesavan、Lakshmi B. Akella、Hao Xu、Eric N. Jacobsen、Lisa A. Marcaurelle

  DOI：10.1021/co300098v

  日期：2012.11.12

  A 2328-membered library of 2,3,4-trisubstituted tetrahydroquinolines was produced using a combination of solution- and solid-phase synthesis techniques. A tetrahydroquinoline (THQ) scaffold was prepared via an asymmetric Povarov reaction using cooperative catalysis to generate three contiguous stereogenic centers. A matrix of 4 stereoisomers of the THQ scaffold was prepared to enable the development

  使用溶液和固相合成技术的组合，生成了2328元的2,3,4-三取代四氢喹啉文库。四氢喹啉（THQ）支架是通过不对称的Povarov反应使用协同催化制备的，以产生三个连续的立体中心。制备了THQ支架的4种立体异构体矩阵，以通过生物学测试建立立体/结构-活性关系（SSAR）。稀疏矩阵设计策略用于选择要合成的文库成员，目的是生成具有适合下游发现的理化性质的四氢喹啉类化合物。